Novartis; local clinical study for combined anti-hypertension drugs.
Published: 2005-05-10 06:56:00
Updated: 2005-05-10 06:56:00
Novartis Korea announced on May 4 to conduct a local clinical study for a combined anti-hypertension drug with Diovan (valsartan), an angiotensin receptor blocker, and Amodipin (amlodipin camsylate), a calcium channel blocker to check its efficacy and safety of Korean patients.
About 130 candi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
